Tinidazole, a synthetic antiprotozoal and antibacterial compound that is nearly insoluble in water, is a BCS class II medication. Because of its poor solubility, tinidazole requires a relatively large oral dosage (2gm). The current study focuses on improving the solubility of tinidazole through the solvent method, which is said to be one of the straightforward methods for doing so by employing different amounts of hydrophilic polymers like poloxamer 188, beta cyclodextrin, sodium carboxymethyl cellulose, and HPMC. The formulation -7, (drug-polaxmer 188) 1:3 complexes had a substantially higher dissolving value of 72.48 percent after 60 minutes, according to the study’s overall findings. It is chosen for more research since it is an optimum formulation. FTIR and DSC investigations were used to verify the medication and carrier compatibility. Tablet dosage forms were created to provide a delayed release of the medication for up to ten hours.The goal was to maximize medication release in the colon and minimize it in the stomach and small intestine. The drug content, drug release, and physicochemical properties of prepared tablet formulations were assessed. Following a drug content check, multimedia dissolution was conducted in several media, including water, 0.1 N HCl, and phosphate buffer. Poloxamer, Eudragit, and HPMC were shown to be able to maintain the release for up to 10 hours, with a final drug release of 78.98%. Comparing the formulations to the pure medication, it was discovered that they improved solubility and dissolution.